Clifford Swan Investment Counsel LLC Acquires Shares of 23,648 Zoetis Inc. $ZTS

Clifford Swan Investment Counsel LLC bought a new position in Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,648 shares of the company’s stock, valued at approximately $3,460,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Halbert Hargrove Global Advisors LLC lifted its stake in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. NewSquare Capital LLC increased its holdings in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the last quarter. Financial Consulate Inc. purchased a new stake in shares of Zoetis in the third quarter worth about $39,000. SJS Investment Consulting Inc. boosted its stake in Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares during the last quarter. Finally, TruNorth Capital Management LLC purchased a new position in Zoetis during the 3rd quarter valued at approximately $42,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ZTS shares. JPMorgan Chase & Co. decreased their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Piper Sandler restated a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Finally, UBS Group set a $136.00 price target on shares of Zoetis in a report on Thursday, January 29th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $129.65 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.00. The company has a market capitalization of $54.73 billion, a price-to-earnings ratio of 21.54, a PEG ratio of 1.97 and a beta of 0.96. The firm’s 50-day moving average is $125.88 and its 200 day moving average is $134.28.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the business earned $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.